论文部分内容阅读
观察了51例急性心肌梗死病人静脉应用尿激酶治疗后，冠状动脉再通组及未通组心电图ST段以及血清肌酸激酶（CK）和肌酸激酶同功酶（CK－MB）的变化规律，并对血管再通组及未通组的临床疗效进行了分析。结果表明：急性心肌梗死病人经静脉溶栓治疗后，冠脉再通组的心电图ST段在用药后30min开始下降，90min下降达53．1％，与未通组心电图ST段具有显著差异；冠脉再通组血清CK及CK－MB在胸痛后14h达到高峰，而未通组在胸病后20h达到高峰；冠脉再通率为67％，再通组心力衰竭、心律失常及病死率明显低于未通组。AMI病人早期经静脉应用溶栓剂治疗，可改善急性期预后，应积极推广。
The changes of electrocardiogram ST segment, serum creatine kinase (CK) and creatine kinase isoenzyme (CK-MB) in coronary artery recanalization group and non-pass coronary artery group were observed after treatment with urokinase in 51 patients with acute myocardial infarction , And the clinical efficacy of recanalization group and failed group were analyzed. The results showed that after intravenous thrombolysis in patients with acute myocardial infarction, ECG ST segment of coronary reperfusion group began to decline 30min after treatment, decreased 90.1% up to 53.1%, with the unresectable ECG ST segment significant difference; the crown The levels of serum CK and CK-MB in pulse reperfusion group reached the peak at 14h after chest pain, while that in non-pass group peaked at 20h after chest disease; the rate of coronary recanalization was 67%; heart failure, arrhythmia and mortality were significantly higher in Reperfusion group Lower than the failed group. AMI patients treated with intravenous thrombolytic therapy early can improve the prognosis of acute phase should be actively promoted.